KeyCorp Analysts Reduce Earnings Estimates for Integer Holdings Co.

Trending News 🌥️

KeyCorp analysts have reduced their earnings estimates for Integer Holdings ($NYSE:ITGR) Co. . The company’s stock has been under pressure lately as investors have become concerned about its exposure to the ongoing trade war between the United States and China. Integer Holdings is a medical device company that manufactures and sells a variety of products, including catheters, pumps, and stents. While the company does have a presence in China, the vast majority of its sales are generated in the United States.

The KeyCorp analysts believe that Integer Holdings’ stock is currently overvalued and that the company will eventually have to lower its guidance. They believe that the trade war will weigh on the company’s results in the second half of the year and that Integer Holdings will report lower-than-expected earnings for the year. The stock is currently trading at around $52 per share.

Earnings

Integer Holdings Co. is a medical device company that manufactures and markets a variety of products and services. KeyCorp analysts recently released their earning report for the company’s FY2022 Q3. As of July 1, Integer Holdings earned 1279.6M USD in total revenue and 78.1M USD in net income. Compared to the same time period last year, this is a 4.8% increase in total revenue and a 19.3% decrease in net income. Integer Holdings’s total revenue has been steadily increasing over the past three years, reaching 1279.6M USD in the most recent quarter.

However, net income has been more volatile, with a 19.3% decrease in the most recent quarter. The company has been investing heavily in research and development, which may account for the decrease in net income. KeyCorp analysts believe that the company’s long-term prospects remain strong, despite the recent decline in earnings.

Price History

On Monday, shares of Integer Holdings Co. opened at $51.60 and closed at $51.10, representing a 0.4% decline from the stock’s previous closing price of $51.30. Integer Holdings is a medical device company that manufactures and sells a variety of products, including cardio and vascular devices, surgical and wound closure devices, and orthopedic devices. KeyCorp’s analysts believe that weaker-than-expected demand for some of Integer Holdings’ products will lead to lower-than-expected earnings for the company.

VI Analysis

Integer Holdings Corporation is a medical device company that develops, manufactures, and markets products and services for use in the interventional cardiology, interventional radiology, and surgical markets. The company’s products include coronary stents, catheters, and other devices. The company’s fundamentals reflect its long term potential. Based on the VI Star Chart, Integer Holdings has an intermediate health score of 6/10 with regard to its cashflows and debt, and is likely to safely ride out any crisis without the risk of bankruptcy.

The company is strong in terms of profitability and growth, but weak in terms of asset and dividend. Integer Holdings is classified as a ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. Such a company may be of interest to investors who are looking for stability and moderate growth potential.

Summary

Integer Holdings is a leading medical device outsource manufacturer. The company’s products are used in a variety of medical procedures, including cardiac rhythm management, vascular intervention, and neuromodulation. Integer Holdings is facing challenging market conditions as a result of the COVID-19 pandemic. Integer Holdings is taking actions to reduce costs and preserve cash flow in response to the pandemic. The company has suspended its stock repurchase program and is focused on reducing discretionary spending. Despite the challenges, KeyCorp analysts believe that Integer Holdings is well-positioned to weather the storm. The company has a strong balance sheet with ample liquidity.

In addition, Integer Holdings is benefiting from a shift in demand away from lower-margin products and towards higher-margin products.